ST. PETERSBURG, Florida, August 18, 2015—Lenstec, Inc.—an established medical device manufacturer of technologically advanced implantable lenses for treating vision disorders—today announced the start of an FDA trial in support of gaining FDA clearance for its Segmented Bi-focal lens (SBL-3).
